Question Everything. See who's reporting it.

Moderna and Merck's mRNA vaccine meets key cancer treatment goals in ongoing trials

Source: Al Jazeera English

The story in brief

Moderna and Merck's mRNA-based cancer vaccine, tested with Keytruda, showed interim results meeting both goals of reducing melanoma recurrence and preventing spread. Over 1.5 million Americans live with melanoma, and the treatment could benefit thousands if approved. Detailed results are expected at a medical meeting, with regulators already in talks. The development marks the first positive late-stage trial for an mRNA cancer vaccine.

2 outletsSee what the other 1 outlet said

NEWXFree on Android and iPhone. Open in NEWX